Evidence map›Paper›PMID 26641029›Full record

ArticleSmall (Weinheim an der Bergstrasse, Germany)2016

Iron-Oxide-Based Nanovector for Tumor Targeted siRNA Delivery in an Orthotopic Hepatocellular Carcinoma Xenograft Mouse Model.

Kui Wang, Forrest M Kievit, Jonathan G Sham, Mike Jeon, Zachary R Stephen, Arvind Bakthavatsalam, James O Park, Miqin Zhang

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Small (Weinheim an der Bergstrasse, Germany), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 70 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Nanoparticles in Gastrooncology.Visceral medicine · 2020
    Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Kui WangDepartment of Materials Science and Engineering, University of Washington, Seattle, WA, 98195, USA.
Forrest M KievitDepartment of Neurological Surgery, University of Washington, Seattle, WA, 98195, USA.
Jonathan G ShamDepartment of Surgery, University of Washington, Seattle, WA, 98195, USA.
Mike JeonDepartment of Materials Science and Engineering, University of Washington, Seattle, WA, 98195, USA.
Zachary R StephenDepartment of Materials Science and Engineering, University of Washington, Seattle, WA, 98195, USA.
Arvind BakthavatsalamDepartment of Biochemistry, University of Washington, Seattle, WA, 98195, USA.
James O ParkDepartment of Surgery, University of Washington, Seattle, WA, 98195, USA.
Miqin ZhangDepartment of Materials Science and Engineering, University of Washington, Seattle, WA, 98195, USA.
University of Washington · USNeurological Surgery · US

Funding

Multifunctional nanoparticles to improve treatment of human glioblastomaR01CA161953 · NCI · UNIVERSITY OF WASHINGTON · PI ZHANG, MIQIN · 2013 to 2017
$1.7M
Nanotechnology and Physical Science Training Program in Cancer ResearchT32CA138312 · NCI · UNIVERSITY OF WASHINGTON · PI ZHANG, MIQIN · 2009 to 2013
$1.5M
Nanovectors For Brain Tumor Diagnosis And TreatmentR01CA134213 · NCI · UNIVERSITY OF WASHINGTON · PI ZHANG, MIQIN · 2007 to 2011
$1.5M
NCI NIH HHS R01 CA134213NCI NIH HHS R01 CA161953NCI NIH HHS R01CA161953NCI NIH HHS T32 CA138312NCI NIH HHS T32CA138312
6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is one of the deadliest cancers worldwide. Small interfering RNA (siRNA) holds promise as a new class of therapeutics for HCC, as it can achieve sequence-specific gene knockdown with low cytotoxicity. However, the main challenge in the clinical application of siRNA lies in the lack of effective delivery approaches that need to be highly specific and thus incur low or no systemic toxicity. Here, a nonviral nanoparticle-based gene carrier is presented that can specifically deliver siRNA to HCC. The nanovector (NP-siRNA-GPC3 Ab) is made of an iron oxide core coated with chitosan-polyethylene glycol (PEG) grafted polyethyleneimine copolymer, which is further functionalized with siRNA and conjugated with a monoclonal antibody (Ab) against human glypican-3 (GPC3) receptor highly expressed in HCC. A rat RH7777 HCC cell line that coexpresses human GPC3 and firefly luciferase (Luc) is established to evaluate the nanovector. The nanoparticle-mediated delivery of siRNA against Luc effectively suppresses Luc expression in vitro without notable cytotoxicity. Significantly, NP-siLuc-GPC3 Ab administered intravenously in an orthotopic model of HCC is able to specifically bound to tumor and induce remarkable inhibition of Luc expression. The findings demonstrate the potential of using this nanovector for targeted delivery of therapeutic siRNA to HCC.

Indexed as

Gene Transfer TechniquesAnimalsAntibodies, MonoclonalCarcinoma, HepatocellularCell Line, TumorFerric CompoundsGene Knockdown TechniquesGene SilencingGenetic VectorsGlypicansHumansLiver NeoplasmsLuciferasesMiceNanoparticlesProton Magnetic Resonance SpectroscopyAntibodies, MonoclonalFerric Compoundsferric oxideGlypicansGPC3 protein, humanLuciferasesRNA, Small Interferingcopolymer polyethyleneimineglypican-3hepatocellular carcinomananoparticlesRNA interference

Identifiers

PMID26641029
PMCPMC4829640
OpenAlexW2193453935

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.